Scopus BioPharma Adds Oligonucleotide Cancer Therapeutics With Olimmune Acquisition

by Vandana Singh, Benzinga Editor

June 30, 2021 11:27 AM | 29 seconds read | Make a Comment

Scopus BioPharma Inc SCPS has acquired Los Angeles-based Olimmune Inc for an undisclosed amount.
Olimmune is a developer of oligonucleotide immunotherapies for treatment-resistant and metastatic cancers.
Olimmune's lead drug candidate, OLIM-01, is being developed for genitourinary and head and neck cancers. INDs for these indications will be submitted by Q1 of 2023.
Olimmune has exclusive, worldwide licenses to certain patents from the City of Hope to develop and commercialize CpG-STAT3ASO and CpG-STAT3decoy.
Price Action: SCPS shares are down 1.12% to $7.05 during the market session on the last check Wednesday.

Posted In: Biotech M&A News Health Care General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.